MALVERN, PA — Maxona Pharmaceuticals has announced the issuance of Patent No. 12,226,421 by the United States Patent and Trademark Office (USPTO) for MAX-001, the company’s breakthrough non-opioid, non-NSAID oral therapy designed to treat acute and chronic pain. With this latest addition, the company now boasts five Method of Use and Composition of Matter patents protecting the development and application of MAX-001’s active ingredient, nefopam.
The newly granted patent bolsters Maxona’s intellectual property strategy, reinforcing its commitment to pioneering non-opioid treatments for pain management. The patent provides legal safeguards for the company’s innovative research and positions Maxona to lead the charge in delivering safer alternatives to traditional pain relief options.
“As a company, one of our priorities has been to develop a strong intellectual property position for MAX-001,” said Shawn Fatholahi, President and CEO of Maxona Pharmaceuticals. “The addition of this new patent further strengthens our intellectual property portfolio. It also underscores our commitment to fully exploring and leveraging the potential of MAX-001 for its initial indications to treat acute and chronic pain as well as other indications in the future.”
MAX-001 represents a notable advancement in the pain management field, addressing a growing need for effective therapies without the risks of opioids or NSAIDs. Its active ingredient, nefopam, is at the heart of this development, and the comprehensive patent protections now in place ensure the ongoing exploration of its potential applications across broader indications.
Looking ahead, Maxona Pharmaceuticals plans to expand its patent portfolio by pursuing additional intellectual property coverage for new formulations and areas of use. This systematic approach aims to enhance MAX-001’s market readiness while advancing the company’s broader mission of providing innovative solutions for pain management. With a strong intellectual foundation and continued R&D efforts, Maxona is well-positioned to significantly impact the field of non-opioid therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.